期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 52, 期 14, 页码 4319-4328出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm900138u
关键词
-
资金
- European COST D39
- Israel Cancer Research Foundation
- Israel Science Foundation [565/03]
- EU-NMR [026145]
Cisplatin is an anticancer drug whose efficacy is limited because tumors develop resistance to the drug. Resistant cells often have elevated levels of cellular glutathione (GSH), believed to be the major cellular target of cisplatin that inactivates the drug by binding to it irreversibly, forming [Pt(SG)(2)] adducts. We show by [H-1, N-15] HSQC that the half-life of N-15 labeled cisplatin in whole cell extracts is similar to 75 min, but no Pt-GSH adducts were observed. When the low molecular mass fraction (<3 kDa) of the extracts was incubated with cisplatin, binding to GSH was observed probably due to removal of high molecular mass platinophiles. Two-thirds of the Pt adducts formed in whole cell extracts, had a molecular mass >3 kDa. [Pt(SG)(2)] cannot account for more than 20% or the Pt adducts. The concentration of reduced thiols in the high molecular mass fraction or the extracts is six times higher than in the low molecular mass fraction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据